Parallel Bio
Using the immune system to cure disease
What they do
Drug discovery and clinical development are slow, costly, and unreliable because animal models often fail to predict human biology and clinical outcomes.
Parallel Bio uses human-first experimental and computational platforms to map human biology and evaluate drug targets and therapies directly in human systems linked to real clinical outcomes.
Pharmaceutical and biotechnology companies developing therapies in cancer and autoimmune disease.
Founders
Robert is a co-founder and CEO of Parallel Bio. Previously he was Director of Strategy & Research Development at Stanford University where he oversaw a $100M scientific portfolio and ran 8 large-scale R&D programs. He also worked in global health and ran vaccine programs with GSK, the NIH, and the Danish government. He completed his postdoctoral training at Stanford, holds a PhD from the University of Pittsburgh, and a BS from the University of Illinois.
Juliana is a co-founder and the CSO of Parallel Bio. She previously worked at System1 Biosciences managing R&D brain organoid drug discovery teams and has extensive experience developing mini-organ systems to better model human disease and discover new drugs.
Open roles 2
Company timeline
- Founded2021
- YC batchSummer 2021
- StatusActive
- Team size20 people
- LocationSan Francisco, CA, USA
Similar startups
